Trial reportNature communications2015
Immunological biomarkers predict HIV-1 viral rebound after treatment interruption.
Trial report in Nature communications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03198325 (Monitored Antiretroviral Pause in Chronic HIV-Infected Subjects With Long-Lasting Suppressed Viremia), which is not on this map. Cited by 127 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Monitored Antiretroviral Pause in Chronic HIV-Infected Subjects With Long-Lasting Suppressed Viremia (APACHE Study)
Who cites it
127 citing papers in PubMed, 2 syntheses or guidelines pooled it, 176 citations in OpenAlex.
- Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies.Nature communications · 2025Pooled it
- Expression Profile and Biological Role of Immune Checkpoints in Disease Progression of HIV/SIV Infection.Viruses · 2022Pooled it
- Vedolizumab and ART in recent HIV-1 infection unveil the role of α4β7 in reservoir size.JCI insight · 2024Trial
- Circulating immune and plasma biomarkers of time to HIV rebound in HIV controllers treated with vesatolimod.Frontiers in immunology · 2024Trial
- Expression of type I interferon-associated genes at antiretroviral therapy interruption predicts HIV virological rebound.Scientific reports · 2022Trial
- Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART.JCI insight · 2020Trial
- Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment.Journal of medical ethics · 2018Trial
- Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B.PloS one · 2017Trial
- Treatment interruption after 2-year antiretroviral treatment initiated during acute/early HIV in infancy.AIDS (London, England) · 2016Trial
- Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection.PLoS pathogens · 2016Trial
- Trial
- Impact of sex differences in adult and paediatric HIV-1 cure.Current opinion in HIV and AIDS · 2026Review
- Article
- Post-treatment SIV control is associated with specific features of viral persistence before and after treatment interruption.Nature communications · 2026Article
- Virus-driven remodeling of the immune microenvironment and response to immune checkpoint inhibitors: the infection- immunity-cancer crosstalk.Frontiers in immunology · 2026Review
- HIV-1 latency reversing agents converge on phosphoregulation of nuclear protein complexes.bioRxiv : the preprint server for biology · 2025Article
- Participant Perspectives in an HIV Treatment Interruption Study in San Francisco, United States.AIDS research and human retroviruses · 2025Article
- Identifying correlates of viral rebound timing and viral control in SHIV-infected infant macaques after ART interruption.Science translational medicine · 2025Article
- Single-cell sequencing insights into the transcriptional landscape of cerebral cavernous malformations.Angiogenesis · 2025Review
- Novel insights into immune checkpoints in HIV/SHIV infection: from SHIVJournal of virology · 2025Article
67 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 9 institutions in 4 countries.
Funding
Abstract
Treatment of HIV-1 infection with antiretroviral therapy (ART) in the weeks following transmission may induce a state of 'post-treatment control' (PTC) in some patients, in whom viraemia remains undetectable when ART is stopped. Explaining PTC could help our understanding of the processes that maintain viral persistence. Here we show that immunological biomarkers can predict time to viral rebound after stopping ART by analysing data from a randomized study of primary HIV-1 infection incorporating a treatment interruption (TI) after 48 weeks of ART (the SPARTAC trial). T-cell exhaustion markers PD-1, Tim-3 and Lag-3 measured prior to ART strongly predict time to the return of viraemia. These data indicate that T-cell exhaustion markers may identify those latently infected cells with a higher proclivity to viral transcription. Our results may open new avenues for understanding the mechanisms underlying PTC, and eventually HIV-1 eradication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.